240 related articles for article (PubMed ID: 31043708)
21. MicroRNA-34a Attenuates Paclitaxel Resistance in Prostate Cancer Cells via Direct Suppression of JAG1/Notch1 Axis.
Liu X; Luo X; Wu Y; Xia D; Chen W; Fang Z; Deng J; Hao Y; Yang X; Zhang T; Zhou L; Wu Y; Wang Q; Xu J; Hu X; Li L
Cell Physiol Biochem; 2018; 50(1):261-276. PubMed ID: 30282072
[TBL] [Abstract][Full Text] [Related]
22. Natural killer cells suppress enzalutamide resistance and cell invasion in the castration resistant prostate cancer via targeting the androgen receptor splicing variant 7 (ARv7).
Lin SJ; Chou FJ; Li L; Lin CY; Yeh S; Chang C
Cancer Lett; 2017 Jul; 398():62-69. PubMed ID: 28373004
[TBL] [Abstract][Full Text] [Related]
23. Unique targeting of androgen-dependent and -independent AR signaling in prostate cancer to overcome androgen resistance.
Lim SC; Jansson PJ; Assinder SJ; Maleki S; Richardson DR; Kovacevic Z
FASEB J; 2020 Sep; 34(9):11511-11528. PubMed ID: 32713076
[TBL] [Abstract][Full Text] [Related]
24. Anti-androgen enzalutamide enhances prostate cancer neuroendocrine (NE) differentiation via altering the infiltrated mast cells → androgen receptor (AR) → miRNA32 signals.
Dang Q; Li L; Xie H; He D; Chen J; Song W; Chang LS; Chang HC; Yeh S; Chang C
Mol Oncol; 2015 Aug; 9(7):1241-51. PubMed ID: 25817444
[TBL] [Abstract][Full Text] [Related]
25. Inhibition of the HER2-YB1-AR axis with Lapatinib synergistically enhances Enzalutamide anti-tumor efficacy in castration resistant prostate cancer.
Shiota M; Bishop JL; Takeuchi A; Nip KM; Cordonnier T; Beraldi E; Kuruma H; Gleave ME; Zoubeidi A
Oncotarget; 2015 Apr; 6(11):9086-98. PubMed ID: 25871401
[TBL] [Abstract][Full Text] [Related]
26. Androgens alter the heterogeneity of small extracellular vesicles and the small RNA cargo in prostate cancer.
Martens-Uzunova ES; Kusuma GD; Crucitta S; Lim HK; Cooper C; Riches JE; Azad A; Ochiya T; Boyle GM; Southey MC; Del Re M; Lim R; Ramm GA; Jenster GW; Soekmadji C
J Extracell Vesicles; 2021 Aug; 10(10):e12136. PubMed ID: 34434533
[TBL] [Abstract][Full Text] [Related]
27. MiR-133a-5p inhibits androgen receptor (AR)-induced proliferation in prostate cancer cells via targeting FUsed in Sarcoma (FUS) and AR.
Zheng L; Kang Y; Zhang L; Zou W
Cancer Biol Ther; 2020; 21(1):34-42. PubMed ID: 31736422
[TBL] [Abstract][Full Text] [Related]
28. PMA induces androgen receptor downregulation and cellular apoptosis in prostate cancer cells.
Itsumi M; Shiota M; Yokomizo A; Takeuchi A; Kashiwagi E; Dejima T; Inokuchi J; Tatsugami K; Uchiumi T; Naito S
J Mol Endocrinol; 2014 Aug; 53(1):31-41. PubMed ID: 24780839
[TBL] [Abstract][Full Text] [Related]
29. Crosstalk between epithelial-mesenchymal transition and castration resistance mediated by Twist1/AR signaling in prostate cancer.
Shiota M; Itsumi M; Takeuchi A; Imada K; Yokomizo A; Kuruma H; Inokuchi J; Tatsugami K; Uchiumi T; Oda Y; Naito S
Endocr Relat Cancer; 2015 Dec; 22(6):889-900. PubMed ID: 26311513
[TBL] [Abstract][Full Text] [Related]
30. Analytical Validation and Clinical Qualification of a New Immunohistochemical Assay for Androgen Receptor Splice Variant-7 Protein Expression in Metastatic Castration-resistant Prostate Cancer.
Welti J; Rodrigues DN; Sharp A; Sun S; Lorente D; Riisnaes R; Figueiredo I; Zafeiriou Z; Rescigno P; de Bono JS; Plymate SR
Eur Urol; 2016 Oct; 70(4):599-608. PubMed ID: 27117751
[TBL] [Abstract][Full Text] [Related]
31. Inhibition of noncanonical Wnt pathway overcomes enzalutamide resistance in castration-resistant prostate cancer.
Chen X; Liu J; Cheng L; Li C; Zhang Z; Bai Y; Wang R; Han T; Huang C; Kong Y; Feng F; Liu X
Prostate; 2020 Feb; 80(3):256-266. PubMed ID: 31856338
[TBL] [Abstract][Full Text] [Related]
32. TCF7 is suppressed by the androgen receptor via microRNA-1-mediated downregulation and is involved in the development of resistance to androgen deprivation in prostate cancer.
Siu MK; Chen WY; Tsai HY; Chen HY; Yin JJ; Chen CL; Tsai YC; Liu YN
Prostate Cancer Prostatic Dis; 2017 Jun; 20(2):172-178. PubMed ID: 28220803
[TBL] [Abstract][Full Text] [Related]
33. Dual targeting of the androgen receptor and hypoxia-inducible factor 1α pathways synergistically inhibits castration-resistant prostate cancer cells.
Fernandez EV; Reece KM; Ley AM; Troutman SM; Sissung TM; Price DK; Chau CH; Figg WD
Mol Pharmacol; 2015 Jun; 87(6):1006-12. PubMed ID: 25829060
[TBL] [Abstract][Full Text] [Related]
34. GLUT1 is an AR target contributing to tumor growth and glycolysis in castration-resistant and enzalutamide-resistant prostate cancers.
Wang J; Xu W; Wang B; Lin G; Wei Y; Abudurexiti M; Zhu W; Liu C; Qin X; Dai B; Wan F; Zhang H; Zhu Y; Ye D
Cancer Lett; 2020 Aug; 485():45-55. PubMed ID: 32428663
[TBL] [Abstract][Full Text] [Related]
35. The Long Non-Coding RNA XIST Interacted with MiR-124 to Modulate Bladder Cancer Growth, Invasion and Migration by Targeting Androgen Receptor (AR).
Xiong Y; Wang L; Li Y; Chen M; He W; Qi L
Cell Physiol Biochem; 2017; 43(1):405-418. PubMed ID: 28869948
[TBL] [Abstract][Full Text] [Related]
36. Targeting the MIF/CXCR7/AKT Signaling Pathway in Castration-Resistant Prostate Cancer.
Rafiei S; Gui B; Wu J; Liu XS; Kibel AS; Jia L
Mol Cancer Res; 2019 Jan; 17(1):263-276. PubMed ID: 30224544
[TBL] [Abstract][Full Text] [Related]
37. Targeting the KIF4A/AR Axis to Reverse Endocrine Therapy Resistance in Castration-resistant Prostate Cancer.
Cao Q; Song Z; Ruan H; Wang C; Yang X; Bao L; Wang K; Cheng G; Xu T; Xiao W; Xiong Z; Liu D; Yang M; Zhou D; Yang H; Chen K; Zhang X
Clin Cancer Res; 2020 Mar; 26(6):1516-1528. PubMed ID: 31796514
[TBL] [Abstract][Full Text] [Related]
38. The inhibitory effects of AR/miR-190a/YB-1 negative feedback loop on prostate cancer and underlying mechanism.
Xu S; Wang T; Song W; Jiang T; Zhang F; Yin Y; Jiang SW; Wu K; Yu Z; Wang C; Chen K
Sci Rep; 2015 Aug; 5():13528. PubMed ID: 26314494
[TBL] [Abstract][Full Text] [Related]
39. Androgen-deprivation therapy with enzalutamide enhances prostate cancer metastasis via decreasing the EPHB6 suppressor expression.
Chen J; Li L; Yang Z; Luo J; Yeh S; Chang C
Cancer Lett; 2017 Nov; 408():155-163. PubMed ID: 28826721
[TBL] [Abstract][Full Text] [Related]
40. ASC-J9(®) suppresses castration resistant prostate cancer progression via degrading the enzalutamide-induced androgen receptor mutant AR-F876L.
Wang R; Lin W; Lin C; Li L; Sun Y; Chang C
Cancer Lett; 2016 Aug; 379(1):154-60. PubMed ID: 27233475
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
